Results 211 to 220 of about 10,792,655 (300)

Clinical Significance of Acute Kidney Injury in Idiosyncratic Drug‐Induced Liver Injury: A Multicentric Propensity Scores Matched Study

Clinical Pharmacology &Therapeutics, EarlyView.
Clinical significance of acute kidney injury in idiosyncratic drug‐induced liver injury: a multicentric propensity scores matched study. Evidence about the role of acute kidney injury (AKI) in idiosyncratic drug‐induced liver injury (DILI) is still scarce.
José María Pinazo‐Bandera, Hao Niu, Juan Pedro Toro‐Ortiz, Inmaculada Medina‐Caliz, Judith Sanabria‐Cabrera, Aída Ortega‐Alonso, Mercedes Robles‐Díaz, Daniel Enrique Di Zeo‐Sanchez, Nelia Hernández, Fernando Bessone, Vinicius Nunes, Raymundo Paraná, M. Isabel Lucena, Raul J. Andrade, Ismael Alvarez‐Alvarez, Miren García‐Cortés   +15 more
wiley   +1 more source

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

Clinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang, Guiling Zhou, Jens H. J. Bos, Eelko Hak, Talitha Feenstra, Frank Klont   +5 more
wiley   +1 more source

Implementation of Pharmacogenomics in Pediatric‐Focused Institutions Within the Pharmacogenomics Global Research Network

Clinical Pharmacology &Therapeutics, EarlyView.
Descriptions of how pediatric‐focused institutions implement pharmacogenomic testing are scarce, and often not differentiated from adult‐focused institutions. We aimed to provide a detailed description of how pediatric‐focused institutions across the world implemented pharmacogenomic testing in clinical practice.
Laura B. Ramsey, Chad Bousman, Rebecca Brand, Kelsey Cook, David B. Gregornik, Cyrine E. Haidar, Nancy Hakooz, Nicole Keuler, Nathan Lamb, Mohamed Nagy, Jenny Q. Nguyen, Courtney Paetznick, April Schultz, D. Max Smith, Evangelia Eirini Tsermpini, Amanda L. Elchynski   +15 more
wiley   +1 more source

The stage- and subgroup-specific impact of non-HLA polymorphisms on preclinical type 1 diabetes progression. [PDF]

Heliyon
Vandewalle J, Desouter AK, Van der Auwera BJ, Chapaza KB, Nobels F, Abrams P, Lebrethon MC, Lapauw B, Keymeulen B, Gorus FK, Van de Casteele M, Belgian Diabetes Registry.   +11 more
europepmc   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

A practical difference from the normal approach to evaluate natural killer (NK) cells and NK cell neoplasms by flow cytometry

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Natural killer (NK) cell neoplasms span indolent to highly aggressive entities, and flow cytometric immunophenotyping is central to their detection and classification. However, distinguishing reactive from neoplastic NK cell expansions can be challenging because NK cells lack somatically recombined antigen receptors, and reactive states may ...
Aaron J. Wilk, Afshin Shameli, Erik Ames, Jonathan R. Fromm, Bartosz Grzywacz, Min Shi, Sindhu Cherian, Jean Oak   +7 more
wiley   +1 more source

Systematic mining and quantification reveal the dominant contribution of non-HLA variations to acute graft-versus-host disease. [PDF]

Cell Mol Immunol
Liang S, Kang YJ, Huo M, Yang DC, Ling M, Yue K, Wang Y, Xu LP, Zhang XH, Xia CR, Li JY, Wu N, Liu R, Dong X, Liu J, Gao G, Huang XJ.   +16 more
europepmc   +1 more source

Old data, new tricks: Comprehensive computational analysis of 10 years of multi‐center EuroFlow acute myeloid leukemia diagnostic immunophenotypic data

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Acute myeloid leukemia (AML) is characterized by high genotypic and immunophenotypic heterogeneity. We collected an extensive dataset containing 5366 flow cytometry files from 885 AML patients, stained with the EuroFlow acute leukemia orientation tube (ALOT) and AML/MDS panel, acquired in a standardized way at eight centers over a period of 10 
Sarah Bonte, Rosan Olsman, Sofie Van Gassen, Sergio Matarraz, Neus Villamor, Stefan Nierkens, Paula Fernandez, Elaine Sobral da Costa, Carmen‐Mariana Aanei, Alberto Orfao, Jacques J. M. van Dongen, Yvan Saeys, Mattias Hofmans, Vincent H. J. van der Velden   +13 more
wiley   +1 more source

HLA and Non-HLA Factors for Donor Selection in Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide GvHD Prophylaxis. [PDF]

Cells
Shike H, Zhang A.
europepmc   +1 more source